HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

BACKGROUND: HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3 + or 2 + with in situ hybridization (ISH) amplification) are treated with HER2 targeted therapies. The concept of HER2-low BC (IHC score 1 + or 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherifi, François, Da Silva, Angélique, Johnson, Alison, Blanc-Fournier, Cécile, Abramovici, Olivia, Broyelle, Antonin, Levy, Christelle, Allouache, Djelila, Hrab, Ioana, Segura, Carine, Morel, Adeline, Villemin, Maud, Boscher, Clémence, Dubot-Poitelon, Coraline, Rottier, Pauline, Lequesne, Justine, Emile, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585737/
https://www.ncbi.nlm.nih.gov/pubmed/36266623
http://dx.doi.org/10.1186/s12885-022-10163-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585737/
https://www.ncbi.nlm.nih.gov/pubmed/36266623
http://dx.doi.org/10.1186/s12885-022-10163-9

Ejemplares similares